Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions

Panelist discusses how health systems can improve communication and coordination among specialists through integrated care models and digital platforms. Centers of Excellence promote health equity by providing specialized care in underserved areas, reducing disparities. A unified approach ensures efficient, patient-centered care, enhancing outcomes for all.

EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa

EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity

EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa

EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa

EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models

EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes

EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management

EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence

Now Viewing

EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions

EP: 12.Navigating HS Management: The Patient Journey

EP: 13.Advancing HS Outcomes: Resource Prioritization and Success Measurement

EP: 14.Tailoring HS Treatment: The Path to Better Patient Outcomes

Video content above is prompted by the following:

• How can health systems ensure seamless communication and coordination among different specialists involved in HS care?
• How can the introduction of Centers of Excellence address health equity issues, particularly in underserved populations?
• Closing thoughts on HS for the AJMC viewing audience.

Related Videos

Related Content

Advertisement

April 7th 2025

Outcomes in Patients With IBD Stratified by Risk of Disease Progression

Tao Fan, PhD Jeanne Jiang, MS Chiahung Chou, PhD Henriette Coetzer, MD Kandavadivu Umashankar, MS Ninfa Candela, MD Jason Wagner, PharmD

This study validates criteria to identify patients with inflammatory bowel disease (IBD) at risk of worsening disease who may benefit from early treatment with advanced therapies.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 3rd 2025

Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative Claims

Poorva M. Nemlekar, MS Katia L. Hannah, PhD, MPH Courtney R. Green, PhD Thomas Grace, MD Peter M. Lynch, MPH Jessica R. Castle, MD Gregory J. Norman, PhD

Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 3rd 2025

FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy

Julia Bonavitacola

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary immunoglobulin A (IgA) nephropathy.

April 3rd 2025

Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease

Julia Bonavitacola

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish efficacy, according to the FDA.

Related Content

Advertisement

April 7th 2025

Outcomes in Patients With IBD Stratified by Risk of Disease Progression

Tao Fan, PhD Jeanne Jiang, MS Chiahung Chou, PhD Henriette Coetzer, MD Kandavadivu Umashankar, MS Ninfa Candela, MD Jason Wagner, PharmD

This study validates criteria to identify patients with inflammatory bowel disease (IBD) at risk of worsening disease who may benefit from early treatment with advanced therapies.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 3rd 2025

Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative Claims

Poorva M. Nemlekar, MS Katia L. Hannah, PhD, MPH Courtney R. Green, PhD Thomas Grace, MD Peter M. Lynch, MPH Jessica R. Castle, MD Gregory J. Norman, PhD

Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 3rd 2025

FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy

Julia Bonavitacola

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary immunoglobulin A (IgA) nephropathy.

April 3rd 2025

Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease

Julia Bonavitacola

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish efficacy, according to the FDA.